We believe Apifiny has the potential to make a real difference in improving the detection of prostate cancer.
Kalamazoo, MI (PRWEB) January 19, 2016
Armune BioScience signed a definitive agreement with Accu Reference Medical Laboratory to offer Apifiny® to their rapidly growing physician account base in over 15 states. Launched in April of 2015, Apifiny is the only cancer specific, non-PSA blood test designed to aid clinicians in the detection of prostate cancer. Apifiny order volume exceeded 3,000 tests in 2015. Primary care physicians and urologists have utilized Apifiny to help move beyond PSA based testing to assess prostate cancer risk.
Armune BioScience, Inc. is a Michigan-based life sciences company that developed Apifiny. Apifiny was developed based on innovative research into the immune system’s response to cancer conducted at the University of Michigan. Armune is currently expanding testing throughout the United States and preparing to expand into several markets worldwide in the coming months.
“Armune is excited to be partnering with Accu Reference to expand access to Apifiny,” commented David Esposito, President and CEO of Armune BioScience. “Accu Reference has an excellent reputation among clinicians and as a result, is one of the fastest growing laboratories in the United States. We look forward to Apifiny supporting their continued rapid growth in the marketplace.”
Physicians normally advise men with increased PSA levels greater than 2.5 ng/mL and an abnormal digital rectal exam to undergo a prostate biopsy. The current process to determine candidates for an initial or repeat biopsy results in too many biopsies being performed in the United States. Apifiny has the potential to aid clinicians in determining the most appropriate candidates for an initial or repeat biopsy and to better address our healthcare system’s demand for improved outcomes at lower costs.
“Accu Reference Medical Lab continues to be a leader in bringing innovative diagnostic tools to our clients and we look forward to offering Apifiny throughout our 15 states area,” said Konstantin Bas, CEO of Accu Reference Medical Lab. “Given the challenges of assessing prostate cancer risk, we believe Apifiny has the potential to make a real difference in improving the detection of prostate cancer.”
Patients who wish to have access to Apifiny should contact their health care provider or contact Accu Reference Medical Laboratory directly at 877-733-4522 Number and (http://www.accureference.com)
About Accu Reference Medical Laboratory (http://www.accureference.com)
Accu Reference is a state-of-the-art medical testing laboratory service that provides a complete range of tests for diagnosis, screening or evaluation of diseases and health conditions. We are certified under the federal government’s Clinical Laboratory Improvement Amendments (CLIA) and operate in compliance with all governmental regulations. We use the latest diagnostic technology.
About Armune BioScience (http://www.armune.com)
Armune BioScience, Inc. is a medical diagnostics company that develops and commercializes unique proprietary technology exclusively licensed from the University of Michigan for diagnostic and prognostic tests for prostate, lung and breast cancers. Armune was incorporated as a Delaware Corporation in 2008 with corporate headquarters in Kalamazoo, MI and a research and commercial laboratory in Ann Arbor, MI.